“Europe spends a substantially lower share of GDP (gross domestic product) on innovative medicines than the US and, as a result, is falling behind in attracting R&D (research and development) and manufacturing investments, putting its ability to protect the health of its own people at risk.”
Drug firm bosses call for price increases in Europe amid tariff uncertainty
